Biotech firm Moderna, which is testing one of many main coronavirus vaccine candidates, priced an providing of 17.6 million new shares at $76 every, the corporate stated late Monday.
The corporate stated it expects the providing to shut round Thursday, with gross proceeds totaling round $1.34 billion. Moderna can also be giving the underwriters a 30-day choice to purchase as much as an extra 2.64 million shares in frequent inventory. Morgan Stanley is the operating the deal.
The announcement comes after Moderna reported optimistic information on its early-stage human trial for a Covid-19 vaccine earlier Monday. The carefully watched vaccine trial produced Covid-19 antibodies in all 45 members, sending the corporate’s inventory surging practically 20% to shut at $80 a share.
In a earlier assertion, Moderna stated it expects to primarily use proceeds from the providing to fund the manufacturing and distribution of its vaccine candidate, mRNA-1273 as soon as it is permitted by federal regulators.
If there are any remaining proceeds, the corporate hopes “to fund scientific improvement and drug discovery in present and new therapeutic areas; to fund additional improvement of its mRNA know-how platform and the creation of recent modalities; or to fund working capital and different common company functions.”
— CNBC’s Christine Wang contributed to this report.